This page was translated automatically from Turkish. Read the original

Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun.

EV1012

Effects of agomelatine tablets combined with paroxetine hydrochloride on SOD and BDNF levels in patients with depression and insomnia

THE EFFECT OF AGOMELATINE TABLETS COMBINED WITH PAROXETINE HYDROCHLORIDE ON THE LEVELS OF SOD AND BDNF IN PATIENTS WITH DEPRESSION AND INSOMNIA

Agomelatine added to paroxetine produced greater improvements in depression and sleep quality scores and greater increases in melatonin, SOD, BDNF, and neurotransmitter levels than eszopiclone.

The study aimed to investigate the effects of agomelatine tablets combined with paroxetine hydrochloride on superoxide dismutase (SOD) and brain-derived neurotrophic factor (BDNF) levels in patients with depression and insomnia. A total of 120 inpatients diagnosed with depression and insomnia at Ning'an Hospital in the Ningxia Hui Autonomous Region between January and December 2021 were divided into a control group of 60 and an experimental group of 60. In addition to standard antidepressant treatment with paroxetine hydrochloride, the experimental group received agomelatine and the control group received eszopiclone for 8 weeks. Depression severity was assessed using the Hamilton Depression Rating Scale (HAMD), and sleep quality using the Pittsburgh Sleep Quality Index (PSQI). Melatonin, SOD, and BDNF levels were measured using an enzyme-linked immunosorbent assay, while norepinephrine (NE), dopamine (DA), and 5-hydroxytryptamine (5-HT) levels were measured using an electrochemiluminescence immunoassay. After eight weeks of treatment, HAMD and PSQI scores were lower in the experimental group than in the control group (P < 0.05), while melatonin, SOD, BDNF, NE, DA, and 5-HT levels were higher (P < 0.05). The authors conclude that combining agomelatine tablets with paroxetine hydrochloride improves depression severity and sleep quality, increases melatonin levels, suppresses oxidative stress, increases BDNF levels, and improves neurotransmitter levels. The poster did not provide numerical means and standard deviations for the groups or information on effect sizes.

Tüm WCP 2026 özetleri